O	0	2	14	14	CD	B-NP
O	2	3	-	-	HYPH	I-NP
O	3	4	3	3	CD	I-NP
O	4	5	-	-	HYPH	I-NP
O	5	10	3zeta	3zeta	NN	I-NP
O	11	25	Overexpression	Overexpression	NN	I-NP
O	26	29	and	and	CC	O
O	30	38	abnormal	abnormal	JJ	B-NP
O	39	43	beta	beta	SYM	I-NP
O	43	44	-	-	HYPH	I-NP
O	44	51	catenin	catenin	NN	B-NP
O	52	62	expression	expression	NN	I-NP
O	63	66	are	be	VBP	B-VP
O	67	77	associated	associate	VBN	I-VP
O	78	82	with	with	IN	B-PP
O	83	87	poor	poor	JJ	B-NP
O	88	103	differentiation	differentiation	NN	I-NP
O	104	107	and	and	CC	I-NP
O	108	119	progression	progression	NN	I-NP
O	120	122	in	in	IN	B-PP
B-Cancer	123	128	stage	stage	NN	B-NP
I-Cancer	129	130	I	I	CD	I-NP
I-Cancer	131	134	non	non	AFX	O
I-Cancer	134	135	-	-	HYPH	O
I-Cancer	135	140	small	small	JJ	B-NP
I-Cancer	141	145	cell	cell	NN	I-NP
I-Cancer	146	150	lung	lung	NN	I-NP
I-Cancer	151	157	cancer	cancer	NN	I-NP
O	157	158	.	.	.	O

O	160	166	Recent	Recent	JJ	B-NP
O	167	174	studies	study	NNS	I-NP
O	175	179	have	have	VBP	B-VP
O	180	185	shown	show	VBN	I-VP
O	186	190	that	that	IN	B-SBAR
O	191	193	14	14	CD	B-NP
O	193	194	-	-	HYPH	I-NP
O	194	195	3	3	CD	I-NP
O	195	196	-	-	HYPH	I-NP
O	196	201	3zeta	3zeta	NN	I-NP
O	202	212	interacted	interact	VBD	B-VP
O	213	217	with	with	IN	B-PP
O	218	223	other	other	JJ	B-NP
O	224	227	key	key	JJ	I-NP
B-Cell	228	236	cellular	cellular	JJ	I-NP
O	237	245	proteins	protein	NNS	I-NP
O	246	254	involved	involve	VBN	B-VP
O	255	257	in	in	IN	B-PP
O	258	261	the	the	DT	B-NP
B-Cancer	262	267	tumor	tumor	NN	I-NP
O	268	279	development	development	NN	I-NP
O	280	283	and	and	CC	I-NP
O	284	295	progression	progression	NN	I-NP
O	295	296	.	.	.	O

O	297	306	Knowledge	Knowledge	NN	B-NP
O	307	309	of	of	IN	B-PP
O	310	312	14	14	CD	B-NP
O	312	313	-	-	HYPH	I-NP
O	313	314	3	3	CD	I-NP
O	314	315	-	-	HYPH	I-NP
O	315	320	3zeta	3zeta	SYM	I-NP
O	321	324	and	and	CC	O
O	325	329	beta	beta	SYM	O
O	329	330	-	-	HYPH	O
O	330	337	catenin	catenin	NN	B-NP
O	338	348	expression	expression	NN	I-NP
O	349	352	and	and	CC	O
O	353	361	clinical	clinical	JJ	B-NP
O	362	374	significance	significance	NN	I-NP
O	375	377	in	in	IN	B-PP
O	378	381	the	the	DT	B-NP
O	382	386	same	same	JJ	I-NP
B-Tissue	387	392	tumor	tumor	NN	I-NP
I-Tissue	393	400	tissues	tissue	NNS	I-NP
O	401	403	is	be	VBZ	B-VP
O	404	411	limited	limit	VBN	B-ADJP
O	411	412	.	.	.	O

O	413	416	The	The	DT	B-NP
O	417	424	purpose	purpose	NN	I-NP
O	425	427	of	of	IN	B-PP
O	428	432	this	this	DT	B-NP
O	433	438	study	study	NN	I-NP
O	439	442	was	be	VBD	B-VP
O	443	445	to	to	TO	B-VP
O	446	457	investigate	investigate	VB	I-VP
O	458	461	the	the	DT	B-NP
O	462	472	expression	expression	NN	I-NP
O	473	476	and	and	CC	I-NP
O	477	489	significance	significance	NN	I-NP
O	490	492	of	of	IN	B-PP
O	493	495	14	14	CD	B-NP
O	495	496	-	-	HYPH	I-NP
O	496	497	3	3	CD	I-NP
O	497	498	-	-	HYPH	I-NP
O	498	503	3zeta	3zeta	SYM	I-NP
O	504	507	and	and	CC	O
O	508	512	beta	beta	SYM	O
O	512	513	-	-	HYPH	O
O	513	520	catenin	catenin	NN	B-NP
O	521	523	in	in	IN	B-PP
O	524	529	stage	stage	NN	B-NP
O	530	531	I	I	CD	I-NP
B-Cancer	532	535	non	non	AFX	O
I-Cancer	535	536	-	-	HYPH	O
I-Cancer	536	541	small	small	JJ	B-NP
I-Cancer	541	542	-	-	HYPH	I-NP
I-Cancer	542	546	cell	cell	NN	I-NP
I-Cancer	547	551	lung	lung	NN	I-NP
I-Cancer	552	558	cancer	cancer	NN	I-NP
O	559	560	(	(	(	O
B-Cancer	560	565	NSCLC	NSCLC	NN	B-NP
O	565	566	)	)	)	O
O	566	567	.	.	.	O

B-Cancer	568	577	Specimens	Specimen	NNS	B-NP
O	578	580	of	of	IN	B-PP
B-Cancer	581	586	NSCLC	NSCLC	NN	B-NP
O	587	590	and	and	CC	O
O	591	599	adjacent	adjacent	JJ	B-NP
O	600	606	normal	normal	JJ	I-NP
B-Tissue	607	611	lung	lung	NN	I-NP
I-Tissue	612	619	tissues	tissue	NNS	I-NP
O	620	624	were	be	VBD	B-VP
O	625	634	collected	collect	VBN	I-VP
O	635	639	from	from	IN	B-PP
O	640	643	110	110	CD	B-NP
O	644	652	patients	patient	NNS	I-NP
O	652	653	.	.	.	O

O	654	657	The	The	DT	B-NP
O	658	669	expressions	expression	NNS	I-NP
O	670	672	of	of	IN	B-PP
O	673	675	14	14	CD	B-NP
O	675	676	-	-	HYPH	I-NP
O	676	677	3	3	CD	I-NP
O	677	678	-	-	HYPH	I-NP
O	678	683	3zeta	3zeta	SYM	I-NP
O	684	687	and	and	CC	O
O	688	692	beta	beta	SYM	O
O	692	693	-	-	HYPH	O
O	693	700	catenin	catenin	NN	B-NP
O	701	705	were	be	VBD	B-VP
O	706	714	detected	detect	VBN	I-VP
O	715	717	by	by	IN	B-PP
O	718	725	western	western	JJ	B-NP
O	726	734	blotting	blotting	NN	I-NP
O	734	735	,	,	,	O
O	736	742	double	double	JJ	B-NP
O	743	751	labeling	labeling	NN	I-NP
O	752	770	immunofluorescence	immunofluorescence	NN	I-NP
O	770	771	,	,	,	O
O	772	780	confocal	confocal	JJ	B-NP
O	781	786	laser	laser	NN	I-NP
O	787	795	scanning	scanning	NN	I-NP
O	796	806	microscopy	microscopy	NN	I-NP
O	807	810	and	and	CC	I-NP
O	811	831	immunohistochemistry	immunohistochemistry	NN	I-NP
O	831	832	.	.	.	O

O	833	836	The	The	DT	B-NP
O	837	847	expression	expression	NN	I-NP
O	848	850	of	of	IN	B-PP
O	851	853	14	14	CD	B-NP
O	853	854	-	-	HYPH	I-NP
O	854	855	3	3	CD	I-NP
O	855	856	-	-	HYPH	I-NP
O	856	861	3zeta	3zeta	NN	I-NP
O	862	865	was	be	VBD	B-VP
O	866	877	upregulated	upregulate	VBN	I-VP
O	878	880	in	in	IN	B-PP
B-Cancer	881	886	stage	stage	NN	B-NP
I-Cancer	887	888	I	I	CD	I-NP
I-Cancer	889	894	NSCLC	NSCLC	NN	I-NP
O	894	895	.	.	.	O

O	896	903	Further	Further	RB	B-ADVP
O	903	904	,	,	,	O
O	905	908	the	the	DT	B-NP
O	909	923	overexpression	overexpression	NN	I-NP
O	924	926	of	of	IN	B-PP
O	927	929	14	14	CD	B-NP
O	929	930	-	-	HYPH	I-NP
O	930	931	3	3	CD	I-NP
O	931	932	-	-	HYPH	I-NP
O	932	937	3zeta	3zeta	NN	I-NP
O	938	948	correlated	correlate	VBD	B-VP
O	949	953	with	with	IN	B-PP
O	954	966	histological	histological	JJ	B-NP
O	967	973	grades	grade	NNS	I-NP
O	973	974	,	,	,	O
B-Multi-tissue_structure	975	980	lymph	lymph	NN	B-NP
I-Multi-tissue_structure	981	985	node	node	NN	I-NP
O	986	996	metastasis	metastasis	NN	I-NP
O	997	1000	and	and	CC	O
O	1001	1005	poor	poor	JJ	B-NP
O	1006	1014	clinical	clinical	JJ	I-NP
O	1015	1022	outcome	outcome	NN	I-NP
O	1022	1023	.	.	.	O

O	1024	1032	Abnormal	Abnormal	JJ	B-NP
O	1033	1043	expression	expression	NN	I-NP
O	1044	1046	of	of	IN	B-PP
O	1047	1051	beta	beta	SYM	B-NP
O	1051	1052	-	-	HYPH	B-NP
O	1052	1059	catenin	catenin	NN	I-NP
O	1060	1063	was	be	VBD	B-VP
O	1064	1077	significantly	significantly	RB	I-VP
O	1078	1088	correlated	correlate	VBN	I-VP
O	1089	1093	with	with	IN	B-PP
O	1094	1098	poor	poor	JJ	B-NP
O	1099	1114	differentiation	differentiation	NN	I-NP
O	1115	1118	and	and	CC	I-NP
B-Multi-tissue_structure	1119	1124	lymph	lymph	NN	I-NP
I-Multi-tissue_structure	1125	1129	node	node	NN	I-NP
O	1130	1140	metastasis	metastasis	NN	I-NP
O	1140	1141	.	.	.	O

O	1142	1150	Abnormal	Abnormal	JJ	B-NP
O	1151	1155	beta	beta	SYM	I-NP
O	1155	1156	-	-	HYPH	I-NP
O	1156	1163	catenin	catenin	NN	B-NP
O	1164	1174	expression	expression	NN	I-NP
O	1175	1178	was	be	VBD	B-VP
O	1179	1189	associated	associate	VBN	I-VP
O	1190	1203	significantly	significantly	RB	B-ADVP
O	1204	1208	with	with	IN	B-PP
O	1209	1217	positive	positive	JJ	B-NP
O	1218	1220	14	14	CD	I-NP
O	1220	1221	-	-	HYPH	I-NP
O	1221	1222	3	3	CD	I-NP
O	1222	1223	-	-	HYPH	I-NP
O	1223	1228	3zeta	3zeta	NN	I-NP
O	1229	1239	expression	expression	NN	I-NP
O	1239	1240	.	.	.	O

O	1241	1243	In	In	IN	B-PP
O	1244	1254	conclusion	conclusion	NN	B-NP
O	1254	1255	,	,	,	O
O	1256	1258	14	14	CD	B-NP
O	1258	1259	-	-	HYPH	I-NP
O	1259	1260	3	3	CD	I-NP
O	1260	1261	-	-	HYPH	I-NP
O	1261	1266	3zeta	3zeta	SYM	I-NP
O	1267	1270	and	and	CC	O
O	1271	1275	beta	beta	SYM	O
O	1275	1276	-	-	HYPH	O
O	1276	1283	catenin	catenin	NN	B-NP
O	1284	1289	might	might	MD	B-VP
O	1290	1294	have	have	VB	I-VP
O	1295	1297	an	an	DT	B-NP
O	1298	1307	important	important	JJ	I-NP
O	1308	1312	role	role	NN	I-NP
O	1313	1315	in	in	IN	B-PP
O	1316	1327	development	development	NN	B-NP
O	1327	1328	,	,	,	O
O	1329	1340	progression	progression	NN	B-NP
O	1341	1344	and	and	CC	O
O	1345	1355	metastatic	metastatic	JJ	B-NP
O	1356	1363	process	process	NN	I-NP
O	1364	1366	of	of	IN	B-PP
B-Cancer	1367	1372	NSCLC	NSCLC	NN	B-NP
O	1372	1373	.	.	.	O

O	1374	1376	14	14	CD	B-NP
O	1376	1377	-	-	HYPH	I-NP
O	1377	1378	3	3	CD	I-NP
O	1378	1379	-	-	HYPH	I-NP
O	1379	1384	3zeta	3zeta	NN	I-NP
O	1385	1390	might	might	MD	B-VP
O	1391	1393	be	be	VB	I-VP
O	1394	1398	used	use	VBN	I-VP
O	1399	1401	as	as	IN	B-PP
O	1402	1412	prognostic	prognostic	JJ	B-NP
O	1413	1423	biomarkers	biomarker	NNS	I-NP
O	1424	1427	for	for	IN	B-PP
B-Cancer	1428	1433	NSCLC	NSCLC	NN	B-NP
O	1433	1434	.	.	.	O

